15 Dec 2009 BOTHELL, Wash., CAMBRIDGE, Mass., and OSAKA, Japan, December 15, 2009 – Seattle Genetics, Inc.(Nasdaq: SGEN) and Millennium: The Takeda [...]

At Seattle Genetics, we are committed to developing innovative antibody-based therapies that improve clinical outcomes for patients with cancer and [...]

Seattle Genetics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies [...]

14 Sep 2010 Under the agreement, Genmab has rights to utilize Seattle Genetics' ADC technology with its HuMax-TF antibody targeting the Tissue Factor [...]

LOS ANGELES, Sept 13 (Reuters) ? Seattle Genetics (SGEN.O) said on Monday it would discontinue development of its experimental drug lintuzumab after a trial found it did not extend the lives of patients with acute myeloid leukemia and [...]

Seattle Genetics achieves milestone under ADC collaboration with Agensys Sun Sep 05 12:46:16 2010 EDT Sep 05, 2010 (Datamonitor via COMTEX) -- Seattle Genetics, a biotechnology company, has achieved a milestone under its antibody-drug [...]

Shares of US biotech firm Seattle Genetics (Nasdaq: SGEN) fell 4.5% to $12.15in morning trading, after the company announced that its Phase IIb clinical trial of lintuzumab (SGN-33) in older patients with acute myeloid leukemia (AML) [...]

DVD?s What Happened to Kerouac? Conquest of America Southwest; Southeast; Northeast; Northwest Citizen Kane [Orson Welles] Un-Broke: What You Need to Know About Money Slavery and the Making of America Egypt Beyond the Pyramids Legacy The Origins of Civilization Indians of the Eastern Woodlands Secre [...]

Send by Tim

Seattle Genetics Inc. (SGEN) - Seattle Genetics and Millennium Announce Positive Top-Line Brentuximab Vedotin (SGN-35) Data from Pivotal Trial in Relapsed and Refractory Hodgkin Lymphoma Harvest Natural Resources Inc. (HNR) - Harvest [...]

Send by bjjSxgrEJU

Seattle Genetics , the developer of targeted antibody drugs, said today it has provided a license to Denmark-based Genmab to develop empowered antibodies. See the article here: Seattle Genetics Snags Genmab Deal | Xconomy. [...]

Family: Grandmother in shooting spree battled schizophrenia Police say a grandmother who killed three family members and herself said nothing before she started her shooting spree that left four dead, including herself. Read more on seattlepi.com Survivor, family mourn for victims of shooting rampag [...]

Send by By ANDREW POLLACK

Seattle Genetics discontinued development of the lintuzumab, saying it had not significantly improved survival for adults with acute myeloid leukemia. [...]

Send by Luke Timmerman

The buzz around Seattle Genetics (NASDAQ: ]) has been about whether it will finally prove, after more than a decade, that an empowered antibody can be an. [...]

Send by Bartcabepep

Seattle Genetics lands research collaboration deal for antibody cancer, Biotech companies Genmab (Copenhagen:GEN) and Seattle Genetics (Nasdaq:SGEN) have entered into a research collaboration agreement for Seattle`s more ? Read more: [...]

Send by BioMedReports.com Staff

Seattle Genetics, Inc. (Nasdaq: SGEN) today after the market closed announced that it will host a conference call and webcast on Monday, September 27, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) regarding top-line [...]

Send by Luke Timmerman

Seattle Genetics (NASDAQ: SGEN) and Cambridge, MA-based Millennium: The Takeda Oncology Company said today that their ?empowered antibody? for blood cancers showed promising results in a small study of patients who were re-treated [...]

Send by Bruce M. Lehr

As reported in Fierce Biotech and Xconomy, Seattle Genetics and GenMab announced a new antibody-drug conjugate (ADC) research collaboration agreement. The deal allows the companies to combine Seattle Genetics ADC teechnology with [...]

Send by Staff Writer

Biotechnology firm Genmab and Seattle Genetics have signed an antibody-drug conjugate (ADC) research collaboration agreement. ADCs are monoclonal antibodies that selectively deliver potent anti-cancer agents to tumor cells. [...]

Send by Sergsander

Genmab and Seattle Genetics Enter Into Antibody-Drug Conjugate Research Collaboration COPENHAGEN, Denmark and BOTHELL, Wash., Sept. 14, 2010 (GLOBE NEWSWIRE)? Summary: Genmab and Seattle Genetics ? Read more? Follow this link: [...]

Send by John Carroll

Seattle Genetics has decided to put its therapy for acute myloid leukemia--lintuzumab, or SGN-33--on the shelf after revealing this morning that the drug failed a Phase IIb study. Analysts quickly concluded that while the trial failure [...]

Seattle Genetics reports positive lymphoma test resultsBizjournals.comSeattle Genetics Inc. announced positive results of its drug targeting relapsed or. [...]

Genmab Helle Husted, Vice President, Investor Relations T: +45 33 44 77 30; M: +45 25 27 47 13; E: [email protected] or Seattle Genetics Peggy Pinkston T: 425-527-4160; E: [email protected]. Copyright Business Wire 2010 [...]

A last-ditch treatment for Hodgkin lymphoma has succeeded in a clinical trial, the drug's developer, Seattle Genetics, announced Monday. The company said in a statement that the drug had reduced tumor burden in 75 percent of patients ? [...]

US HOT STOCKS: ArcSight, Seattle Genetics, Dollar Thrifty Wall Street Journal US stocks were higher Monday as the Dow Jones Industrial Average gained 88 points to 10551, the S&P 500 rose 1% to 1121 and the Nasdaq Composite climbed 1.5% [...]

Seattle Genetics, Inc. (NASDAQ: SGEN) is one of those companies in the world of biotech and biohealth which some have believed would be an ultimate takeover target. The issue is that some companies either do not have enough funding on [...]